Soleno Therapeutics Faces Class Action Lawsuit Over DCCR Disclosures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Source: PRnewswire
Soleno Therapeutics Inc. has seen a significant price increase of 33.73% in pre-market trading, reaching a 20-day high.
The company is currently facing a securities class action lawsuit due to disappointing disclosures about its DCCR drug (VYKAT™ XR), which has raised concerns among investors regarding the safety and efficacy of the treatment. The lawsuit alleges that Soleno concealed significant safety risks during clinical trials, leading to investor dissatisfaction and a potential impact on the company's market confidence.
This legal challenge could have serious implications for Soleno's future, as it may affect investor trust and the company's ability to secure financing, especially given the recent history of stock price volatility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
